Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ELOVL1 | Q9BW60 | 4/20 | 0.46 |
| ▸ | TBK1 | Q9UHD2 | 7/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775301 | 0.88 | ELOVL1 (0.42) | CYP2C19ELOVL1SMN1; SMN2 | |
| SCHEMBL30775260 | 0.87 | ELOVL1 (0.43) | CYP2C19ELOVL1SMN1; SMN2 | |
| SCHEMBL18615748 | 0.80 | CYP2C19 (0.58) | CYP2C19ELOVL1KMOLRRK2HTT | |
| Hydrochloric Acid SCHEMBL20357286 | 0.79 | CYP2C19 (0.57) | CYP2C19ELOVL1KMOLRRK2HTT | |
| Hydrochloric Acid SCHEMBL20357289 | 0.79 | CYP2C19 (0.57) | CYP2C19ELOVL1KMOLRRK2HTT | |
| SCHEMBL10202519 | 0.75 | ACACB (0.44) | CYP2C19ELOVL1 | |
| SCHEMBL30775324 | 0.74 | SYK (0.48) | TBK1JAK2LRRK2SYK | |
| Hydrochloric Acid SCHEMBL622191 | 0.74 | ACACB (0.44) | CYP2C19ELOVL1LRRK2 | |
| SCHEMBL20357324 | 0.73 | CYP2C19 (0.50) | CYP2C19ELOVL1KMO | |
| SCHEMBL4462897 | 0.73 | CYP2C19 (0.58) | CYP2C19ELOVL1KMOLRRK2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | CYP2C19 1243/4885ELOVL1 208/4885TBK1 1784/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | CYP2C19 1243/4885ELOVL1 208/4885TBK1 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.